Cerus Corporation says it is considering a variety of possibilities for its immunotherapy development programs, ranging from partnering up with other companies to merging the programs with another company or even spinning it off into a new company. Cerus says it has three cancer immunotherapeutic candidates, one of which entered Phase I human clinical trials in 2006 and a second aiming for an IND in mid-2007. The company intends to focus on blood safety.
"This potential corporate realignment is intended to provide opportunities for Cerus to more fully realize the potential value of our immunotherapy business, while allowing us to focus resources on our commercial-stage blood safety business," said Claes Glassell, president and CEO of Cerus.
- read the release from Cerus